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This perspective was adapted from a Career Achievement Award talk given at the
International Cannabinoid Research Society Symposium in Bukovina, Poland on June
27, 2016. As a biochemist working in the neurosciences, I was always fascinated
with neurotransmitter inactivation. In 1993 we identified an enzyme activity that breaks
down anandamide. We called the enzyme anandamide amidase, now called FAAH. We
and other laboratories developed FAAH inhibitors that were useful reagents that also
proved to have beneficial physiological effects and until recently, new generations of
inhibitors were in clinical trials. Nearly all neurotransmitters are water soluble and as
such, require a transmembrane protein transporter to pass through the lipid membrane
for inactivation inside the cell. However, using model systems, we and others have
shown that this is unnecessary for anandamide, an uncharged hydrophobic molecule
that readily diffuses across the cellular membrane. Interestingly, its uptake is driven by
the concentration gradient resulting from its breakdown mainly by FAAH localized in the
endoplasmic reticulum. We identified the FABPs as intracellular carriers that “solubilize”
anandamide, transporting anandamide to FAAH. Compounds that bind to FABPs block
AEA breakdown, raising its level. The cannabinoids (THC and CBD) also were discovered
to bind FABPs and this may be one of the mechanisms by which CBD works in childhood
epilepsy, raising anandamide levels. Targeting FABPs may be advantageous since they
have some tissue specificity and do not require reactive serine hydrolase inhibitors, as
does FAAH, with potential for off-target reactions. At the International Cannabis Research
Society Symposium in 1992, Raphe Mechoulam revealed that his laboratory isolated an
endogenous lipid molecule that binds to the CB1 receptor (cannabinoid receptor type
1) and this became the milestone paper published in December of that year describing
anandamide (AEA, Devane et al., 1992). As to be expected, this discovery raised the
issues of AEA’s synthesis and breakdown.
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ANANDAMIDE SYNTHESIS
At first we mistakenly reported an enzymatic activity
independent of the fatty acid amide hydrolase (FAAH) and
calcium for the synthesis of AEA (Deutsch and Chin, 1993),
but then followed up with collaborators to help elucidate the
correct pathways. This misstep was caused by the condensation
of ethanolamine with phenylmetylsulfony fluoride, whose
product ran the same as AEA on thin layer chromatography
(Bill Devane, personal communication circa 1994). The first
demonstration of AEA synthesis via a calcium dependent
N-acyl phosphatidylethanolamine-specific phospholipase D
(NAPE-PLD) mechanism was reported in 1994 (Di Marzo et al.,
1994) although this activity had been characterized with other
phosphatidylethanolamines (Schmid et al., 1983). This enzyme
was purified and cloned (Ueda et al., 2005) and subsequent
papers using null mice confirmed that it was mainly responsible
for the synthesis of AEA (Tsuboi et al., 2011; Leishman et al.,
2016) although other minor pathways may be involved under
certain conditions (Liu et al., 2008; Simon and Cravatt, 2010)
depending upon the mouse construct (Leishman et al., 2016).
FAAH can also mediate the reverse reaction for the synthesis
of AEA and this has been implicated physiologically in liver
regeneration (Devane and Axelrod, 1994; Arreaza et al., 1997;
Izzo and Deutsch, 2011; Mukhopadhyay et al., 2011).
ANANDAMIDE BREAKDOWN
(ANANDAMIDE AMIDASE, FAAH)
In 1993 an enzyme we called anandamide amidase, now named
called FAAH, was shown to break AEA down to arachidonic acid
and ethanolamine (Figure 1) in the membrane fractions of most
rat tissues except in leg and heart muscle (Deutsch and Chin,
1993). This activity was reported in liver microsomes for fatty
acid amides, other than anandamide (Bachur and Udenfriend,
1966; Schmid et al., 1985). This lack of breakdown activity in
muscle was fortuitous for the success of the vas deferens assay
that was employed in the discovery of AEA in 1992 (Devane et al.,
1992; Pertwee et al., 1995). In our original assay we used thin layer
chromatography with AEA radio-labeled in the arachidonate
portion of the molecule, but later ethanolamine labeled AEA
simplified the assay procedure by permitting measurement of
radiolabel without a thin layer chromatography step (Omeir et al.,
1995). Cloning of the enzyme permitted more detailed molecular
studies including ones that showed uniquely two serine residues
in the active site (Omeir et al., 1999; Patricelli et al., 1999) and that
FAAH was localized to the endoplasmic reticulum (Cravatt et al.,
1996). FAAH is the main player in AEA inactivation although
other pathways have been implicated in the metabolism of AEA
as well (van der Stelt et al., 2002; Rahman et al., 2014).
Abbreviations: NAPE-PLD, N-acyl phosphatidylethanolamine-specific
phospholipase D; NSAID, Nonsteroidal anti-inflammatory drug; AEA
anandamide; FAAH, fatty acid amide hydrolase; FABP, fatty acid binding
protein; ER, endoplasmic reticulum; CB receptor, cannabinoid receptor; COX-2,
cyclooxygenase 2; NAAA, N-acylethanolamine-hydrolyzing acid amidase; 2-AG,
2-arachidonylglycero; tetrahydrocannabinol, THC; cannabidiol, CBD.
EARLY FAAH INHIBITORS
Phenylmethylsulfonyl fluoride (PMSF) was the first FAAH
inhibitor, discovered serendipitously. When added to protect
FAAH from proteolytic degradation in membrane fractions it
had the opposite effect, completely inactivating the enzyme
(Deutsch and Chin, 1993; Childers et al., 1994). PMSF was
subsequently shown to raise AEA levels and have physiological
activity and was surprisingly widely used in preclinical studies
(70 PubMed references up to 2016) in spite of it being highly
non-specific (Vann et al., 2012). The first systematic synthesis
of FAAH inhibitors was undertaken at Stony Brook University
in 1994 by Bohumir Koutek who made a series of fatty acid
ethanolamides, α-keto ethanoamides, α-keto ethyl esters, and
trifluoromethyl ketones, all reversible inhibitors. Arachidonyl
trifluoromethyl ketone, the most specific, gave 100% inhibition
at 7.5µM (Ki = 650 nM) and Allyn Howlett, a co-author,
found that it also bound to CB1 with only 21% occupancy
at 10µM. From studies with these transition state inhibitors,
we knew that AEA was cleaved by a serine hydoxyl group
on the enzyme. Realizing the clinical implications of raising
AEA levels with inhibitors, the last sentence of our paper
read: “The development of inhibitors that block the breakdown
of anandamide may be significant therapeutically in any of
the areas that 19-tetrahydrocannabinol and anandamide has
been shown to play a role, including analgesia, mood, nausea,
memory, appetite, sedation, locomotion, glaucoma, and immune
function” (Koutek et al., 1994). Shortly thereafter, a series of fatty
acid sulfonyl fluorides were synthesized with palmitylsulfonyl
fluoride (AM374) being a 1000-fold more potent FAAH inhibitor
than PMSF but did bind to CB1 (IC50 for AM374 was 520
nM using [3H]CP-55,940 in rat forebrain membranes, Deutsch
et al., 1997a; Deutsch and Makriyannis, 1997). Also around this
time, we and another group reported that methyl arachidonyl
fluorophosphonate (MAFP) was a potent irreversible inhibitor
(De Petrocellis et al., 1997; Deutsch et al., 1997b), an inhibitor
that was later used for the crystallization of FAAH (Bracey et al.,
2002). A series of MAFP analogs were synthesized and short
chain saturated derivatives exhibited the highest in vivo potency
(C8:0 and C12:0, Martin et al., 2000). Around this time the first
report of NSAIDs inhibiting FAAH was published as well as a
review covering other inhibitors (Fowler et al., 1997; Boger et al.,
1999; Ueda et al., 2000).
LATER FAAH INHIBITORS AND CLINICAL
TRIALS
The “golden age,” with hundreds of FAAH inhibitors developed,
followed these early reports, in part as a result of cloning,
crystal structure determination, and the development of assays
(activity-based protein profiling to determine off-target reactions,
Cravatt et al., 1996; Leung et al., 2003; McKinney and Cravatt,
2005; Mileni et al., 2008; Fowler, 2015). These inhibitors
compromise, for example; α-ketoheterocycle, carbamate (e.g.,
URB597), aryl and piperidine/piperazine ureas (e.g., PF-
3845, PF-04457845), azetidine urea, azetidine, boronic acid,
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FIGURE 1 | The Hydrolysis of Anandamide to Arachidonic Acid and Ethanolamine by FAAH.
azole, and ethylaminopyrimidines, and tetrahydronaphthyridine,
derivatives from a variety of academic and industrial institutions
(Khanna and Alexander, 2011; Fowler, 2015; Lodola et al., 2015).
Recently, Phase 1 clinical trials with BIA 10-2474 (from the Bial
pharmaceutical company) were terminated owing to the death
and sickening of some volunteers (Casassus, 2016). However, a
Phase 2 trial with the Pfizer FAAH inhibitor PF-04457845 was
completed and the compound was well tolerated in osteoarthritis
patients but there was a lack of analgesic effect in the knee
(Huggins et al., 2012). Johnson and Johnson suspended its Phase
2 clinical trial with JNJ-42165279 for anxiety and depression
owing to the Bial results, as did Pfizer with PF-04457845 for
Tourette Syndrome and cannabis dependence trials.
CELLULAR UPTAKE OF ANANDAMIDE IS
COUPLED TO ITS BREAKDOWN BY FAAH
The uptake of AEA into cells is unique in that its uptake
is coupled to its breakdown by the catabolic enzyme FAAH
located at the endoplasmic reticulum (Figure 2). Uptake rates
in different cells are generally correlated with inherent FAAH
concentration and the rate increases further with transfection
of FAAH (Day et al., 2001; Deutsch et al., 2001). Conversely,
uptake rates are generally negatively correlated with the degree
of FAAH inhibition, although in some cells other catabolic
enzymes and their inhibitors may play a role, such as COX-
2 and NAAA (Fowler et al., 2004, 2013; Glaser et al., 2005;
Hillard and Jarrahian, 2005). FAAH removes AEA from inside
the cell, disrupting the equilibrium between inside and outside
the cell, generating a concentration gradient that drives uptake
(Figure 2).
TRANSMEMBRANE TRANSPORTERS
In 1993 we were the first to show, with rather rudimentary
experiments, that AEA was actively taken up in neuroblastoma
and glioma cells (Deutsch and Chin, 1993). In 1994 the
uptake of AEA was confirmed and the mechanism was
postulated to involve an ATP independent active membrane
transporter (Di Marzo et al., 1994). The hypothesis of an AEA
transmembrane transporter became dogma for many years and
the “hunt” still goes on for this “putative” anandamidemembrane
transporter (AMT) also called the “putative endocannabinoid
membrane transporter (EMT, Ligresti et al., 2010; Nicolussi
et al., 2014; Nicolussi and Gertsch, 2015). Many of the AMT
(EMT) proposals have fallen by the wayside. For example,
a paper first showed uptake was FAAH independent and
then a decade later it was proposed that a FAAH fragment
called FLAT (FAAH-like anandamide transporter) was the
transmembrane transporter (Fegley et al., 2004; Fu et al., 2012),
the latter being questioned (Leung et al., 2013; Björklund
et al., 2014; Fowler, 2014). The evidence for a transmembrane
transporter was based on enzyme saturation kinetics in cell
culture, uptake studies in cells and the physiological effects
of “membrane transporter inhibitors.” Many dozens of such
inhibitors were proposed. However, it was shown that the kinetics
of uptake of AEA can show saturation owing to the passage
of hydrophobic AEA through the water layer surrounding
the cell and that many of these transport inhibitors were
in fact FAAH inhibitors or FAAH substrates or bound to
receptors confounding the mechanism of their physiological
effects (Glaser et al., 2003; Alexander and Cravatt, 2006; Bojesen
and Hansen, 2006; Nicolussi and Gertsch, 2015). Furthermore,
it was demonstrated that AEA can freely pass through an
artificial membrane without the aid of any protein (Figure 2,
Bojesen and Hansen, 2005; Di Pasquale et al., 2009; Kaczocha
et al., 2012a; Fowler, 2013, 2015). A transmembrane protein
transporter has not been identified to date and the effects of
these inhibitors appear to occur downstream and many of the
so-called transporter inhibitors were in fact FAAH or FABP
inhibitors.
FABPS: INTRACELLULAR
TRANSPORTERS FOR ANANDAMIDE
FABPs are “workhorse” proteins for shuttling lipids inside the
cell (Furuhashi and Hotamisligil, 2008). From the observation
that cultured cells accumulate AEA in excess of that found
in the media, we and others postulated that cells may have
an intracellular binding protein(s) (Hillard and Jarrahian,
2000; Rakhshan et al., 2000; Deutsch et al., 2001). In 2009,
FABPs were identified by us to be intracellular carriers
for AEA (Figure 2). Our conclusion was based upon the
observation that AEA uptake and hydrolysis were significantly
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FIGURE 2 | Schematic of Anandamide Uptake and Inactivation. Endogenous anandamide (AEA) passes through the cellular membrane without the need for a
protein transporter and is shuttled through the aqueous environment of the cytoplasm with the fatty acid binding protein transporters (FABPs) to endoplasmic
reticulum (ER) localized fatty acid amide hydrolase (FAAH) for catabolism. FAAH drives the uptake and inhibition of FAAH or the FABPs reduces the rate of anandamide
breakdown and raises the AEA levels for signaling at the receptor.
potentiated in N18TG2 neuroblastoma cells after overexpression
of FABP5 or FABP7 or in COS-7 cells stably expressing FAAH.
Administration of the competitive FABP ligand oleic acid
or the non-fatty acid FABP inhibitor BMS309403 attenuated
AEA uptake and hydrolysis confirming the roles of FABP
as AEA carriers (Kaczocha et al., 2009). Shortly thereafter,
molecular dynamics simulations of AEA in complex with
FABP7 showed that the carboxamide oxygen of AEA can
interact with FABP7 interior residues R126 and Y128, while
the hydroxyl group of AEA can interact with FABP7 interior
residues, T53 and R106 (Howlett et al., 2011). Using more
detailed structural crystallographic studies we determined
that AEA (as well as 2-AG) bound to key amino acid
residues consistent with that observed for fatty acids and the
corresponding polar groups for the endocannabinoids (Sanson
et al., 2014).
INHIBITORS OF THE FABPS AND BINDING
OF CANNABINOIDS
Specific inhibitors of the FABPs were developed at Stony Brook
such as SBFI26 that led to an increase in AEA levels in the brains
of animals and had physiological effects. As shown in Figure 2,
inhibiting the FABPs will reduce the AEA delivery to FAAH and
disrupt the outward/inward concentration gradient driven by
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FAAH. Intriguingly, the truxillic acid structure of SBFI26 is the
core structure of (−)-incarvillateine, the active component from
a Chinese herb used for rheumatism (Berger et al., 2012). It was
found that some of the inhibitors (such as OMDM1, OMDM2,
VDM11, AM1172, AM404) of the “putative” transmembrane
transporter, inhibit FABPs, perhaps explaining, in part, their
mechanism of action (Kaczocha et al., 2012b).
Recently, again using computational analysis and ligand
displacement assays, we showed that human FABP3, 5, and 7 bind
THC and CBD and function as intracellular carriers (Elmes et al.,
2015). Furthermore, we demonstrated that THC and CBD inhibit
the cellular uptake and catabolism of AEA by targeting FABPs.
This competition for FABPs may in part or wholly explain the
increased circulating levels of AEA reported after consumption
of cannabidiol (Leweke et al., 2012). These data may explain,
in part, the action of CBD in modulating the endocannabinoid
tone in vivo and its reported efficacy toward epilepsy and other
neurological disorders (Ibeas Bih et al., 2015). The role of the
FABP as carriers for endocannabinoids and particularly AEA will
undoubtedly grow as illustrated in the liver where FABP1 also
serves as an AEA carrier (Schroeder et al., 2016).
THE FUTURE
Inhibition of FAAH or FABPs decrease the breakdown of AEA
leading to less cellular uptake and prolonged physiological effects.
The Bial clinical trial has temporarily set back the approach of
employing a FAAH inhibitor. However, other FAAH inhibitors
have been shown to be safe in Phase 2 clinical studies and
these may be pursued in the future for indications, for example,
such stress-related disorders. FABP inhibitors provide another
approach for raising AEA levels. Since FABPs have some tissue
specificity, it may be possible to design inhibitors that target
specific organs, such as the brain, more easily than with FAAH
inhibitors.
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